Table 3.
Performance of RISK6 signature compared to Interferon-γ release assays: QuantiFERON-TB Gold Plus (QFT-P) and recombinant Mtb-HBHA expressed in Mycobacterium smegmatis (IGRAs-rmsHBHA).
| Intended application | Test | Sensitivity% | Specificity% | PPV% | NPV% | Cases, n | Controls, n | AUC | AUC 95%CI |
|---|---|---|---|---|---|---|---|---|---|
| ATB vs (LTBI + HD) | RISK6 | 90.90 | 87.7 | 87 | 91.5 | 44 | 49 | 94.1 | 89.3–98.8 |
| QFT-P | 67.50 | 46.9 | 50.9 | 63.9 | 40 | 49 | 57.2 | 45.2–69.1 | |
| (ATB + LTBI) vs HD | RISK6 | 90.00 | 30.4 | 79.7 | 50 | 66 | 23 | 77.8 | 68.5–87.1 |
| QFT-P | 80.30 | 100 | 100 | 63.9 | 70 | 23 | 90.1 | 83.9–96.3 | |
| ATB vs treated TB | RISK6 | 90.1 | 72.2 | 82.5 | 83.3 | 141 | 97 | 90.9 | 87.2–94.5 |
| IGRAs-rmsHBHA | 83.8 | 59.8 | 70.3 | 76.5 | 136 | 87 | 75.3 | 68.6–82 |
ATB active TB, LTBI latent TB infection, HD healthy donors, vs versus, rmsHBH recombinant Mtb HBHA expressed in, PPV positive predictive value, NPV negative predictive value.